Kaufmann Robert, Bozer Amber Harris, Jotte Amanda Kube, Aqua Keith
Midwest Allergy Sinus Asthma PC, Springfield, IL, USA.
Department of Psychological Sciences, Tarleton State University, Stephenville, TX, USA.
Med Cannabis Cannabinoids. 2023 Aug 16;6(1):77-88. doi: 10.1159/000531666. eCollection 2023 Jan-Dec.
Self-dosing of off-the-shelf cannabidiol (CBD) for a myriad of health conditions is common in the USA. These CBD products are often mislabeled, suggesting that much less or much more CBD is being consumed than indicated on the label. This study examined the relationship between long-term self-dosing of CBD and (a) indications and, when a verified concentration of CBD is being consumed, (b) the daily CBD dosage, (c) the impact on general health and symptoms, and (d) over-the-counter (OTC) and prescription (Rx) drug usage.
US adults 18-75 years of age who had used unverified CBD products for >1 month were recruited to participate in this decentralized, observational, IRB-approved study and provided a concentration-verified CBD product of their choice from 15 different vendors for 4 weeks. Prior to receiving product, they were queried on their primary reason for use (PRfU), primary symptom for use (PSfU), general health score (GHS), symptom score (SS), OTC and Rx drug use, and daily CBD dose. Individuals were queried daily on OTC and Rx drug use and CBD dose and weekly on SS and GHS prior to (pre-CBD) and after (post-CBD) ingestion of CBD on that day.
The PRfU included chronic pain, mental health, general health and wellness, sleep disorders, the central nervous system, digestive health, and others, while the PSfU included anxiety, back and/or joint pain, sleep, inflammation, and others. The mean daily dose was normally distributed, with a mean, median, and range of 53.1, 40.8, 8-390 mg/day, respectively. For both GHS and SS, the post-CBD was significantly higher than the pre-CBD score for each category of PRfU. The GHS scores did not change over the study, but pre- and post-CBD SS improved over time, with pre-improving more than post-CBD SS. The percentage of individuals decreasing or completely stopping OTC drugs or Rx drugs over the 4 weeks was 31.2% and 19.2%, respectively, with those taking CBD for chronic pain, decreasing drug use the most. OTC and Rx drug usage decreased when the CBD dose was changed and when GHS and SS improved.
Pain, mental health (primarily anxiety/stress), and sleep are the most common reasons for CBD use. Self-administration of CBD reduced OTC and Rx drug usage at daily doses less than those reported in controlled studies. CBD self-administration significantly improves self-perception of general health and decreases symptom severity, and as these improve, fewer OTC and Rx drugs are used.
在美国,自行服用非处方大麻二酚(CBD)来治疗多种健康状况的情况很常见。这些CBD产品常常标签有误,这意味着实际摄入的CBD量比标签上标注的要少得多或多得多。本研究调查了长期自行服用CBD与(a)使用指征之间的关系,以及当摄入经核实浓度的CBD时,(b)每日CBD剂量、(c)对总体健康和症状的影响,和(d)非处方(OTC)及处方(Rx)药物使用情况之间的关系。
招募了18至75岁使用未经核实的CBD产品超过1个月的美国成年人,参与这项经机构审查委员会(IRB)批准的去中心化观察性研究,并从15个不同供应商处为他们提供其选择的经浓度核实的CBD产品,为期4周。在收到产品之前,询问他们使用的主要原因(PRfU)、使用的主要症状(PSfU)、总体健康评分(GHS)、症状评分(SS)、OTC和Rx药物使用情况以及每日CBD剂量。在当天摄入CBD之前(CBD前)和之后(CBD后),每天询问个体的OTC和Rx药物使用情况以及CBD剂量,每周询问SS和GHS情况。
使用的主要原因包括慢性疼痛、心理健康、总体健康和保健、睡眠障碍、中枢神经系统、消化健康等,而使用的主要症状包括焦虑、背部和/或关节疼痛、睡眠、炎症等。每日平均剂量呈正态分布,均值、中位数和范围分别为53.1、40.8、8 - 390毫克/天。对于GHS和SS,在每种PRfU类别中,CBD后的得分均显著高于CBD前的得分。GHS评分在研究过程中没有变化,但CBD前后的SS随时间有所改善,CBD前改善得比CBD后更多。在4周内减少或完全停用OTC药物或Rx药物的个体百分比分别为31.2%和19.2%,其中因慢性疼痛服用CBD的个体减少药物使用的情况最为明显。当CBD剂量改变以及GHS和SS改善时,OTC和Rx药物的使用量减少。
疼痛、心理健康(主要是焦虑/压力)和睡眠是使用CBD最常见的原因。自行服用CBD在每日剂量低于对照研究报告的剂量时,可减少OTC和Rx药物的使用。自行服用CBD能显著改善对总体健康的自我认知并减轻症状严重程度,随着这些情况的改善,使用的OTC和Rx药物也会减少。